There has been a lot going on with drugs in the GLP-1 agonist class over the past few months. First we added Tanzeum (albiglutide) as a once-a-week drug. Then the new Bydureon pen was introduced, and finally, Lilly got their once-weekly auto-injector pen product Trulicity (dulaglutide) approved by the FDA. This means there are now six different ways for you to deliver these medications to your patients. This month we have prepared a handy table that you can use to make the right decision for your patients. I also encourage you to click on the links to each PI to evaluate further how your patients would benefit from these medications.